These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32878528)

  • 21. Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.
    Liu Y; Wang BC; Zuppan CW; Chau P; Fitts J; Chinnock R; Wang J
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA class I associations with EBV+ post-transplant lymphoproliferative disorder.
    Jones K; Wockner L; Thornton A; Gottlieb D; Ritchie DS; Seymour JF; Kumarasinghe G; Gandhi MK
    Transpl Immunol; 2015 Mar; 32(2):126-30. PubMed ID: 25731678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Rare Case of Classical Hodgkin Lymphoma Diagnosed 10 Years after Liver Transplant.
    Zhang L; Pereira Mestre R; Bihl F; Bühler M; Vannata B; Stathis A
    Case Rep Oncol; 2017; 10(3):923-927. PubMed ID: 29279693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
    Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
    Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation.
    Akbas A; Tiede C; Lemound J; Maecker-Kolhoff B; Kreipe H; Hussein K
    Transpl Int; 2015 Nov; 28(11):1299-307. PubMed ID: 26147593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders.
    Nalesnik MA
    Recent Results Cancer Res; 2002; 159():9-18. PubMed ID: 11785849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-transplant lymphoproliferative disorders are not associated with IgG4 sclerosing disease.
    Cathro HP; Bullock GC; Bonatti H; Meriden Z; Cook S; Aguilera N
    Transpl Infect Dis; 2014 Dec; 16(6):897-903. PubMed ID: 25298125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Kabasawa N; Shiozawa E; Murai S; Homma M; Uesugi Y; Matsui T; Nakata A; Shimada S; Sasaki Y; Baba Y; Watanuki M; Arai N; Fujiwara S; Kawaguchi Y; Tsukamoto H; Uto Y; Yanagisawa K; Hattori N; Sakai H; Harada H; Nakamaki T; Takimoto M; Yamochi-Onizuka T
    J Clin Exp Hematop; 2021; 61(3):120-125. PubMed ID: 34511544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.